The Future of JAK Inhibitors

Will JAK inhibitors triumph over persisting regulatory roadblocks to offer patients a new treatment option?

From blockbuster drugs to black box warnings, Janus kinase inhibitors (JAKs) have seen dramatic highs and lows in their journey to market access across the last few years. This innovative drug class has faced dizzying twists, turns and falls within the landscape of safety acceptability. Yet despite the hurdles JAKs are facing, pharma’s conviction in their potential to generate a paradigm shift in patient care means R&D activity and interest remains undaunted.

Driven by the sheer scale of the Immune-Mediated Inflammatory Diseases (IMIDs) treatment market and clear scenario of unmet patient need, the JAKs pipeline currently comprises no fewer than 45 therapeutic candidates. 1 In different stages of development, they are in a whole slew of IMID fields – and their journey is far from over.

JAK inhibitors are an oral class of therapeutics exciting to biopharma companies, investors, patients and physicians alike. Clinical results promise patients in multiple indications effective and more convenient treatment options. The first assets to enter the market, with approval for Rheumatoid Arthritis (RA), were tofacitinib (now also approved for Psoriatic Arthritis and Ulcerative Colitis) and baricitinib, followed by upadacitinib (RA).

First-generation JAKs have proven spectacularly efficacious both in clinical trials and in the clinic in treating inflammatory and autoimmune diseases – however, nearly all are facing an imbalance between safety and efficacy.

The result? JAKs’ rise in market success – for now – has hit unexpected turbulence.

Deallus JAK Inhibitors White Paper
DOWNLOAD WHITEPAPER

You may also be interested in…

Revolutionizing Blood Cancer Treatment: A Dive into Cutting-Edge Therapies

World Blood Cancer Day [28 May 2024] serves as a stark reminder of the significant challenges faced by the millions battling these life-threatening diseases. Here at Deallus, we have been privileged enough to partner with many leading companies in this space to support the development of lifechanging therapies across haemato-oncology.

The need for innovation in Women’s Health

Women’s Health Week (14-20 May 2024) provides an opportunity to reflect on the changing landscape for the access, treatment, and representation of women across healthcare. We’re proud that many of the clients we are partnering with are part of driving much needed change and reform within Women’s Health, lending our experience and expertise to the innovation that is required.

A message from our Chairwoman

At Deallus we are fortunate to have Ulrike Meier as our Chairwoman since 2020. Ulrike has written a brilliant blog reflecting on her time with Deallus so far and shares some insights into, even if removed from daily business, as Chairwoman, there is room to make a difference. From being authentic, focusing on the bigger picture, to providing motivation and guidance, Ulrike explores what key elements she prioritises in her role and how we can all play a part in organisation success.